Table IV.

Age of diagnosis of melanoma and pancreatic cancer in individuals with cyclin-dependent kinase inhibitor 2A mutations

Study	Study location	High-risk CDKN2A negative family (range), y*	CDKN2A positive family (range), y
Melanoma
Burden et al,93 1999†	United Kingdom (Scotland)	51 mean	37 mean
Ghiorzo et al,94 1999	Italy (Liguria)	47 median	48 median‡
Goldstein et al,95 2000	United States (various)	nd	34.2 median§
Hashemi et al,82 2000‡	Sweden	54 median	42 median
Vasen et al,8 2000†	Netherlands	44 (12–71) mean	39 (15–72) mean
Auroy et al,83 2001	France	44.1 (17–75) mean	43.9 (28–60) mean
Bish op et al,5 2002	GenoMEL	nd	37.5 (12–86) mean
Blackwood et al,84 2002	United States (Pennsylvania)	50 mean	39.7 mean
Mantelli et al,63 2002†	Italy (northern and central)	48 median	42 median
Rulyak et al,10 2003	United States (various)	nd	51 median
Ghiorzo et al,13 2004†	Italy (Liguria)	49.4 mean	46.5 mean
Mantelli et al,77 2004†	Italy (Liguria)	47 median	41 median
Lang et al,67 2005	United Kingdom (Scotland)	46 mean	35 mean
Puig et al,86 2005	Spain	45.8 (± 16.1) mean	32.9 (± 12.6) mean
Gold stein et al,4 2006	GenoMEL	45 median	36 median
Niendorf et al,72 2006	United States (Massachusetts)	44.4 (95% CI 42.0–46.9) mean	33.2 (95% CI 25.9–40.5) mean
Pancreas
Vasen et al,8 2000†	Netherlands	nd	58 (38–77) mean
de Vos tot Nederveen Cappel et al,96 2003†	Netherlands	nd	58 (43–74) mean
Rulyak et al,10 2003	United States (various)	nd	59 median

CDKN2A, Cyclin-dependent kinase inhibitor 2A; CI, confidence interval; nd, not discussed.

Bolded studies reflect large consortium-based data sets.

^*CDKN2A negative families fulfilled the same eligibility criteria as CDKN2A positive families; study dependent.

^†Population in which common mutation accounts for majority of CDKN2A mutations identified.

^‡Median age of diagnosis in general population was 60 y.

^§Median age of diagnosis in general population was 54 y.